This article is more than 5 years old. Information may no longer be current.
Glycemic control similar with VIAject insulin vs. regular human insulin
Click Here to Manage Email Alerts
ADA 70th Scientific Sessions
ORLANDO — Patients with type 2 diabetes who took VIAject insulin, a fast-absorbed human insulin formulation, achieved similar glycemic control, but significantly better weight loss and a twofold reduction in the rate of hypoglycemia compared with patients who took regular human insulin, according to a study presented here.
Helena W. Rodbard, MD, and colleagues observed a –0.56% reduction in HbA1c with VIAject insulin (Biodel) vs. –0.70 with regular human insulin. However, patients assigned to VIAject had an adjusted mean weight change of just 0.46 compared with 1.35 among patients assigned to regular human insulin.
The researchers presented data on the safety and efficacy of both insulin formulations when used in combination with previously prescribed insulin glargine, metformin and/or thiazolidinedione therapy. The 6-month, open-label, parallel-group, multicenter study included 471 patients with type 2 diabetes.
The rate of non-severe hypoglycemia was significantly lower with VIAject insulin (0.33 events per month) compared with regular human insulin (0.66 events per month; P<.02).
There were no remarkable between-group differences in fasting plasma glucose, seven-point glucose profiles or the percentage of patients who reached an HbA1c goal of <7%.
Patients in the VIAject insulin group reported greater irritation and pain at the injection site compared with patients in the regular human insulin group. However, this adverse event rate declined as the study progressed, according to the researchers.
“These findings are encouraging and suggest that we can achieve proper glycemic control with reduced hypoglycemia and weight gain through the use of a more rapid-acting form of human insulin,” Rodbard, practicing endocrinologist and medical director, Endocrine and Metabolic Consultants, Rockville, Md., said during the oral session. “These results represent a meaningful advance in the treatment of type 2 diabetes.”
For more information:
- Rodbard HW. 36-OR. Presented at: American Diabetes Association 70th Scientific Sessions; June 25-29, 2010; Orlando.
Follow
EndocrineToday.com on Twitter.